Document is current
Any future updates will be listed below
-
Authors
Clarke, Lauren http://orcid.org/0000-0003-2647-6819
Gesundheit, Neil http://orcid.org/0009-0004-0478-0785
Sherr, Elliott H.
Hardan, Antonio Y.
Parker, Karen J. http://orcid.org/0000-0002-6836-6338
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD091972, HD091972)
U.S. Department of Defense (W81XWH-21-1-0210)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
- License Information
-
More Information
Article History
Received: 26 September 2023
Revised: 23 February 2024
Accepted: 26 February 2024
First Online: 7 March 2024
Competing interests
: LC, NG, and EHS have no interests to declare. AYH declares consulting fees from Quadrant Bio, IAMA therapeutics, and Beaming Health. AYH and KJP are receiving Vasostrict from Endo International free of charge for use in an investigator-initiated, NIH-funded phase IIb clinical trial that is evaluating the safety and efficacy of vasopressin treatment to improve social abilities in children with ASD. The Board of Trustees of the Leland Stanford Junior University has filed patent applications related to data reviewed herein: PCT/US2019/019029 (“Methods for diagnosing and determining severity of an autism spectrum disorder”) and PCT/US2019/041250 (“Intranasal Vasopressin Treatment for Social Deficits in Children with Autism”). These patents have not been granted, nor licensed, and no author is receiving financial compensation at this time.
